| WB | 1/500-1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/50-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | ERCC1; DNA excision repair protein ERCC-1 |
| Entrez GeneID | 2067 |
| WB Predicted band size | Calculated MW: 33 kDa; Observed MW: 36 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse |
| Immunogen | A synthesized peptide derived from human ERCC1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于ERCC1抗体的3-4篇参考文献的简要总结：
---
1. **文献名称**：*DNA Repair by ERCC1 in Non-Small-Cell Lung Cancer and Cisplatin-Based Adjuvant Chemotherapy*
**作者**：Olaussen, K.A. et al.
**摘要**：该研究通过免疫组化分析非小细胞肺癌(NSCLC)患者肿瘤组织中ERCC1蛋白的表达，发现ERCC1低表达的患者在接受顺铂辅助化疗后生存期显著延长，表明ERCC1可作为化疗敏感性的预测标志物。
2. **文献名称**：*ERCC1 and Thymidylate Synthase mRNA Levels Predict Survival for Colorectal Cancer Patients Receiving Combination Oxaliplatin and Fluorouracil Chemotherapy*
**作者**：Shirota, Y. et al.
**摘要**：研究分析了结直肠癌患者肿瘤中ERCC1 mRNA水平与奥沙利铂化疗疗效的关系，发现ERCC1高表达与较差的治疗反应和生存率相关，提示其可用于个性化化疗方案的选择。
3. **文献名称**：*ERCC1 Immunohistochemistry in Clinical Applications: A Review of Analytical Parameters and Performance*
**作者**：Varma, M. et al.
**摘要**：该文献系统评估了多种ERCC1抗体的特异性和重复性，强调不同抗体在检测中的差异性，为临床研究中选择可靠抗体提供了方法学指导。
4. **文献名称**：*ERCC1 Expression in Breast Cancer: A Predictive Marker of Response to Platinum-Based Chemotherapy*
**作者**：Bhargava, R. et al.
**摘要**：研究发现乳腺癌患者中ERCC1蛋白低表达与铂类药物化疗敏感性显著相关，支持其作为乳腺癌化疗疗效预测的潜在生物标志物。
---
这些文献涵盖了ERCC1抗体在癌症预后评估、化疗敏感性预测及抗体特异性验证等方向的应用。
ERCC1 (Excision Repair Cross-Complementation Group 1) is a critical enzyme in the nucleotide excision repair (NER) pathway, a DNA repair mechanism that removes bulky DNA adducts caused by UV radiation, environmental carcinogens, or chemotherapeutic agents like platinum-based drugs. The ERCC1 protein forms a heterodimeric complex with XPF (xeroderma pigmentosum group F complementation protein), which is essential for cleaving damaged DNA strands during NER. Dysregulation of ERCC1 is linked to impaired DNA repair capacity and has been associated with cancer susceptibility, treatment resistance, and clinical outcomes.
ERCC1 antibodies are widely used in research and diagnostics to evaluate ERCC1 protein expression levels, particularly in cancer tissues. Clinically, ERCC1 expression has been studied as a predictive biomarker for resistance to platinum-based chemotherapy (e.g., cisplatin, oxaliplatin) and alkylating agents. Low ERCC1 levels are generally correlated with better therapeutic responses, though this varies across cancer types. However, inconsistent clinical data highlight challenges in standardizing detection methods (e.g., immunohistochemistry, Western blot) and interpreting results, partly due to antibody specificity issues and the existence of multiple ERCC1 splice variants with distinct functions.
Beyond its role in DNA repair, ERCC1 participates in other cellular processes, including interstrand crosslink repair and maintaining genomic stability. Its involvement in chromosome segregation and immune system function further complicates its biological profile. Despite these complexities, ERCC1 antibodies remain vital tools for exploring DNA repair mechanisms and developing personalized oncology strategies.
×
